$2.97
0.56% today
Nasdaq, Aug 12, 09:10 pm CET
ISIN
US53630X1046
Symbol
LPCN

Lipocine, Inc. Stock price

$2.95
-0.32 9.65% 1M
-0.46 13.49% 6M
-1.93 39.55% YTD
-1.06 26.43% 1Y
-9.00 75.32% 3Y
-33.09 91.81% 5Y
-292.34 99.00% 10Y
-847.05 99.65% 20Y
Nasdaq, Closing price Mon, Aug 11 2025
+0.02 0.68%
ISIN
US53630X1046
Symbol
LPCN
Industry

Key metrics

Basic
Market capitalization
$16.0m
Enterprise Value
$-3.7m
Net debt
positive
Cash
$19.7m
Shares outstanding
5.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.4 | 19.6
EV/Sales
negative | negative
EV/FCF
0.7
P/B
0.8
Financial Health
Equity Ratio
93.3%
Return on Equity
0.0%
ROCE
-33.7%
ROIC
-6,468.5%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$3.7m | $814.5k
EBITDA
$-6.4m | -
EBIT
$-6.5m | $-10.3m
Net Income
$-5.4m | $-9.7m
Free Cash Flow
$-5.6m
Growth (TTM | estimate)
Revenue
-22.1% | -92.7%
EBITDA
37.9% | -
EBIT
37.6% | -787.9%
Net Income
40.1% | -97,000.0%
Free Cash Flow
-1.1%
Margin (TTM | estimate)
Gross
-
EBITDA
-174.7% | -
EBIT
-176.0%
Net
-146.1% | -1,189.3%
Free Cash Flow
-152.3%
More
EPS
$-1.0
FCF per Share
$-1.0
Short interest
1.9%
Employees
16
Rev per Employee
$700.0k
Show more

Is Lipocine, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Lipocine, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Lipocine, Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Lipocine, Inc. forecast:

Buy
88%
Hold
13%

Financial data from Lipocine, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
3.67 3.67
22% 22%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.55 4.55
12% 12%
124%
- Research and Development Expense 5.59 5.59
43% 43%
152%
-6.42 -6.42
38% 38%
-175%
- Depreciation and Amortization 0.05 0.05
25% 25%
1%
EBIT (Operating Income) EBIT -6.47 -6.47
38% 38%
-176%
Net Profit -5.37 -5.37
40% 40%
-146%

In millions USD.

Don't miss a Thing! We will send you all news about Lipocine, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lipocine, Inc. Stock News

Neutral
PRNewsWire
7 days ago
SALT LAKE CITY , Aug. 5, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced financial results for the second quarter ended June 30, 2025 and provided a corporate update. Neuroactive Steroids LPCN 1154 (oral brexanolone product candidate) is a no...
Neutral
PRNewsWire
about 2 months ago
Phase 3 Top Line Results Expected Q2 2026 SALT LAKE CITY , June 26, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to develop innovative products with effective oral delivery, today announced that the first patient has been dosed in its pivotal Phase 3 clinical trial of LPCN 1154 (oral brexanolone), its investigation...
Neutral
PRNewsWire
about 2 months ago
SALT LAKE CITY , June 23, 2025 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics, today announced that it will host a virtual research and development (R&D) investor event on Wednesday, July 9, 2025 at 11:00 AM ET featuring Kristina M. Deligiannidis, MD (Zucker Hillside Hospi...
More Lipocine, Inc. News

Company Profile

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development for the delivery of drugs using proprietary delivery technology. The firm involves in applying oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. It offers TLANDO, an oral testosterone replacement therapy. The company was founded in 2011 and is headquartered in Salt Lake City, UT.

Head office United States
CEO Mahesh Patel
Employees 16
Founded 2011
Website www.lipocine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today